Jennison Associates LLC Trims Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Jennison Associates LLC trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 21.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 410,057 shares of the company's stock after selling 110,333 shares during the period. Jennison Associates LLC owned about 1.43% of Krystal Biotech worth $74,643,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. EFG Asset Management North America Corp. increased its holdings in Krystal Biotech by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company's stock worth $2,308,000 after acquiring an additional 60 shares during the last quarter. GAMMA Investing LLC grew its stake in Krystal Biotech by 160.3% in the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock valued at $28,000 after buying an additional 93 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Krystal Biotech by 11.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company's stock valued at $173,000 after acquiring an additional 94 shares during the period. Arizona State Retirement System lifted its position in shares of Krystal Biotech by 2.1% during the second quarter. Arizona State Retirement System now owns 5,147 shares of the company's stock worth $945,000 after acquiring an additional 108 shares in the last quarter. Finally, Fiera Capital Corp lifted its position in shares of Krystal Biotech by 0.8% during the second quarter. Fiera Capital Corp now owns 16,208 shares of the company's stock worth $2,976,000 after acquiring an additional 130 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now directly owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 14.10% of the stock is currently owned by company insiders.

Krystal Biotech Trading Up 1.4 %

KRYS opened at $180.61 on Thursday. Krystal Biotech, Inc. has a 12 month low of $99.00 and a 12 month high of $219.34. The business's 50-day moving average price is $180.03 and its 200-day moving average price is $181.99. The company has a market cap of $5.19 billion, a P/E ratio of 100.62 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business's quarterly revenue was up 879.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.67) EPS. Equities research analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on KRYS shares. Citigroup lifted their target price on Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. Stifel Nicolaus boosted their price target on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Evercore ISI increased their price objective on Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a research report on Monday, August 12th. Chardan Capital boosted their target price on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a research report on Monday, August 5th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $202.29.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).